JP2005506298A - Ｅｇ５阻害剤を用いる増殖性疾患の治療方法 - Google Patents

Ｅｇ５阻害剤を用いる増殖性疾患の治療方法 Download PDF

Info

Publication number
JP2005506298A
JP2005506298A JP2002576907A JP2002576907A JP2005506298A JP 2005506298 A JP2005506298 A JP 2005506298A JP 2002576907 A JP2002576907 A JP 2002576907A JP 2002576907 A JP2002576907 A JP 2002576907A JP 2005506298 A JP2005506298 A JP 2005506298A
Authority
JP
Japan
Prior art keywords
alkyl
group
compound
arylalkyl
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2002576907A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005506298A5 (enExample
Inventor
スペンサー・デイビッド・キンボール
ルイス・ジェイ・ロンバード
デイビッド・ビー・ローリンズ
ハイ−ユン・シャオ
デボラ・エル・ルーセル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2005506298A publication Critical patent/JP2005506298A/ja
Publication of JP2005506298A5 publication Critical patent/JP2005506298A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2002576907A 2001-03-29 2002-03-28 Ｅｇ５阻害剤を用いる増殖性疾患の治療方法 Withdrawn JP2005506298A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27995601P 2001-03-29 2001-03-29
US28036601P 2001-03-30 2001-03-30
PCT/US2002/009817 WO2002078639A2 (en) 2001-03-29 2002-03-28 A method of treating proliferative diseases using eg5 inhibitors

Publications (2)

Publication Number Publication Date
JP2005506298A true JP2005506298A (ja) 2005-03-03
JP2005506298A5 JP2005506298A5 (enExample) 2005-12-22

Family

ID=26959985

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002576907A Withdrawn JP2005506298A (ja) 2001-03-29 2002-03-28 Ｅｇ５阻害剤を用いる増殖性疾患の治療方法

Country Status (7)

Country Link
US (1) US20020165240A1 (enExample)
EP (1) EP1372657A4 (enExample)
JP (1) JP2005506298A (enExample)
CA (1) CA2442455A1 (enExample)
IL (1) IL158083A0 (enExample)
MX (1) MXPA03008691A (enExample)
WO (1) WO2002078639A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040009156A1 (en) * 2001-10-12 2004-01-15 Christoph Reinhard Antisense therapy using oligonucleotides that target human kinesin genes for treatment of cancer
ATE480527T1 (de) * 2001-12-11 2010-09-15 Kyowa Hakko Kirin Co Ltd Thiadiazolinderivate zur krebsbehandlung
US7199107B2 (en) * 2002-05-23 2007-04-03 Isis Pharmaceuticals, Inc. Antisense modulation of kinesin-like 1 expression
KR101096948B1 (ko) 2003-04-18 2011-12-20 후지필름 홀딩스 가부시끼가이샤 Ｍ기 키네신 저해제
CA2528433A1 (en) * 2003-06-10 2004-12-23 Kyowa Hakko Kogyo Co., Ltd. Thiadiazoline derivative
WO2005007124A2 (en) 2003-07-23 2005-01-27 Bristol-Myers Squibb Company Substituted dihydropyrimidine inhibitors of calcium channel function
US7166603B2 (en) 2003-07-23 2007-01-23 Bristol-Myers Squibb Co. Dihydropyrimidone inhibitors of calcium channel function
US20050100508A1 (en) * 2003-11-12 2005-05-12 Nichols M. J. Methods for identifying drug combinations for the treatment of proliferative diseases
US20050158320A1 (en) * 2003-11-12 2005-07-21 Nichols M. J. Combinations for the treatment of proliferative diseases
US7662581B1 (en) 2003-12-18 2010-02-16 Novartis Vaccines And Diagnostics, Inc. Eg5 co-crystals
DK1761515T3 (da) * 2003-12-20 2009-02-16 Merck Patent Gmbh 2-(hetero-)aryl-substituerede tetrahydroquinolinderivater
EP2343384A3 (en) * 2004-03-23 2012-01-04 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancer
DE102004021637A1 (de) * 2004-05-03 2005-12-01 Merck Patent Gmbh Dihydrobenzothiophene
CN101027309B (zh) 2004-08-18 2010-10-27 阿斯利康(瑞典)有限公司 所选择的稠合嘧啶酮的对映体和在治疗和预防癌症中的用途
WO2006074293A2 (en) * 2005-01-07 2006-07-13 President And Fellows Of Harvard College Bicyclic dihydropyrimidines as eg5 inhibitors
CN101193878A (zh) * 2005-03-22 2008-06-04 协和发酵工业株式会社 实体肿瘤治疗剂
CN101193877A (zh) * 2005-03-22 2008-06-04 协和发酵工业株式会社 造血系统肿瘤治疗剂
WO2006137490A1 (ja) * 2005-06-24 2006-12-28 Kyowa Hakko Kogyo Co., Ltd. 再狭窄治療剤
DE102006002065B4 (de) * 2006-01-16 2007-11-29 Infineon Technologies Austria Ag Kompensationsbauelement mit reduziertem und einstellbarem Einschaltwiderstand
WO2007107543A1 (en) 2006-03-22 2007-09-27 Janssen Pharmaceutica N.V. Inhibitors of the interaction between mdm2 and p53
MX2010012931A (es) 2008-05-30 2011-02-24 Dana Farber Cancer Inst Inc Metodos para tratar una enfermedad asociada con quinesina meiotica.
BR112012029326A2 (pt) 2010-05-20 2017-08-08 Astrazeneca Ab processo para a preparação de animais olefínicas substituídas por arila
RU2427373C1 (ru) * 2010-11-08 2011-08-27 Виктор Вениаминович Тец Средство для индукции эндогенного интерферона
CN113135859B (zh) * 2021-04-26 2022-08-26 安徽省庆云医药股份有限公司 一种绿色合成瑞舒伐他汀钙中间体的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2658804A1 (de) * 1976-12-24 1978-07-06 Bayer Ag Kreislaufbeeinflussende mittel
EP0330470A3 (en) * 1988-02-24 1992-01-02 Ajinomoto Co., Inc. 1,4-dihydropyridine derivatives useful against tumour cells
US5536724A (en) * 1992-03-03 1996-07-16 Sri International Antiinflammatory and antineoplastic 5-deazaaminopterins and 5,10-dideazaaminopterins
US5767131A (en) * 1993-04-05 1998-06-16 Synaptic Pharmaceutical Corporation Dihydropyridines and new uses thereof

Also Published As

Publication number Publication date
CA2442455A1 (en) 2002-10-10
MXPA03008691A (es) 2003-12-12
EP1372657A2 (en) 2004-01-02
WO2002078639A2 (en) 2002-10-10
EP1372657A4 (en) 2005-11-09
IL158083A0 (en) 2004-03-28
WO2002078639A3 (en) 2003-04-10
US20020165240A1 (en) 2002-11-07

Similar Documents

Publication Publication Date Title
US20020165240A1 (en) Method of treating proliferative diseases using Eg5 inhibitors
EP2454236B1 (en) 3-oxo-2,3-dihydro-1h-isoindole-4-carboxamides as parp inhibitors
EP2655378B1 (en) Compounds and their use as bace inhibitors
JP2019085414A (ja) Ｋｒａｓ ｇ１２ｃの共有結合性阻害剤
JP4294960B2 (ja) 抗癌剤としてのサイクリン依存性キナーゼ阻害剤
RS20050944A (sr) Derivati pirazolo- hinazolina,postupci za njihovo dobijanje i njihova upotreba kao inhibitora kinaze
CN101679448A (zh) 螺吲哚满酮衍生物
MX2011012187A (es) Derivados de isoquinolin-1(2h)-ona como inhibidores de poli(adp-ribosa) polimerasa (parp-1).
EP2454237B1 (en) 3-oxo-2,3,-dihydro-1h-isoindole-4-carboxamides with selective parp-1 inhibition
US6900214B2 (en) Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
JP2002508780A (ja) 新規な化合物
US6809102B2 (en) Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
EP2736896B1 (en) 3-oxo-2,3-dihydro-1h-indazole-4-carboxamide derivatives as parp-1 inhibitors
HU221811B1 (hu) N-acilezett-piperidin-származékok, eljárás ezek előállítására, és ezeket tartalmazó gyógyászati készítmények
JPH06500099A (ja) Ｃｎｓ疾病の処置におけるヘテロ環状アミノ―アルコール化合物の使用
CN115745955A (zh) 嘧啶酮类化合物、其制备方法及其在医药上的应用
FR2862968A1 (fr) Derives de 4-[(arylmethyl)aminomethyl]piperidine, leur preparation et leur application en therapeutique
AP982A (en) Quinoxalinediones.
AU2002248724A1 (en) A method of treating proliferative diseases using Eg5 inhibitors
EP4161905A1 (en) Substituted (phthalazin-1-ylmethyl)ureas, substituted n-(phthalazin-1-ylmethyl)amides, and analogues thereof
KR100589967B1 (ko) 항암제로 사용되는 3-아미노-6-메틸-인다졸 유도체
CN121002026A (zh) 吡咯并吡嗪化合物、其制备及其治疗用途
AU2002258636A1 (en) Novel cyano-substituted dihydropyrimidine compounds and their use to treat diseases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050316

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050316

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20051206